相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Wnt pathway activation and ABCB1 expression account for attenuation of Proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells
Kowit Yu Chong et al.
CANCER BIOLOGY & THERAPY (2015)
Novel therapeutic strategies for multiple myeloma
Naoya Mimura et al.
EXPERIMENTAL HEMATOLOGY (2015)
Current therapeutic strategies for multiple myeloma
Yoshihiro Torimoto et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2015)
The effect of the PI3K inhibitor BKM120 on tumour growth and osteolytic bone disease in multiple myeloma
Sally Martin et al.
LEUKEMIA RESEARCH (2015)
Anti-β2-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy
Mingjun Zhang et al.
ONCOTARGET (2015)
Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib
Ilyas Sahin et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance
Feda Azab et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
J. Zhu et al.
CURRENT MEDICINAL CHEMISTRY (2014)
Bortezomib in multiple myeloma: systematic review and clinical considerations
T. C. Kouroukis et al.
CURRENT ONCOLOGY (2014)
Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease
Antonio Garcia-Gomez et al.
ONCOTARGET (2014)
Dissecting Bortezomib: Development, Application, Adverse Effects and Future Direction
Biyin Cao et al.
CURRENT PHARMACEUTICAL DESIGN (2013)
A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo
J. Glauer et al.
BLOOD CANCER JOURNAL (2013)
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment
Abdel Kareem Azab et al.
BLOOD (2012)
Molecular crosstalk between the proteasome, aggresomes and autophagy: Translational potential and clinical implications
James J. Driscoll et al.
CANCER LETTERS (2012)
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone
Yuhuan Zheng et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2012)
Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Bortezomib Combination Therapy in Multiple Myeloma
Prashant Kapoor et al.
SEMINARS IN HEMATOLOGY (2012)
Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
T. Ishii et al.
BLOOD CANCER JOURNAL (2012)
Multiple Myeloma
Jacob Laubach et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
D. Chen et al.
CURRENT CANCER DRUG TARGETS (2011)
Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide
Chad C. Bjorklund et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway
A. M. Martelli et al.
LEUKEMIA (2011)
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer
Matthew T. Burger et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
PI3K/p110δ is a novel therapeutic target in multiple myeloma
Hiroshi Ikeda et al.
BLOOD (2010)
Once-versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
Craig B. Reeder et al.
BLOOD (2010)
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
Paul G. Richardson et al.
BLOOD (2010)
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-κB activity in myeloma cells
Stephanie Markovina et al.
MOLECULAR CANCER (2010)
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
Abdel Kareem Azab et al.
BLOOD (2009)
Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia
Tomasz Rzymski et al.
CELL CYCLE (2009)
Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
C. B. Reeder et al.
LEUKEMIA (2009)
Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Haitao Meng et al.
LEUKEMIA & LYMPHOMA (2008)
The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines
Antonino Neri et al.
LEUKEMIA & LYMPHOMA (2008)
Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma
C. S. Chim et al.
LEUKEMIA (2007)
A phase 2 study of bortezomib in relapsed, refractory myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
